Børre Fevang

Børre Fevang is a Professor in the Department of Rheumatology and Infectious Diseases at the University of Oslo. His research focuses on immunodeficiency disorders, particularly Common Variable Immunodeficiency (CVID), HIV, and inflammatory diseases. He investigates mechanisms of immune dysregulation, including cytokine regulation, chemokines (e.g., CCL19, CCL21), and molecular pathways in chronic inflammation. His work spans clinical outcomes, molecular biology, and translational medicine.

Key research interests include CVID-associated complications (e.g., lung disease, metabolic disturbances), HIV pathogenesis, and the role of complement systems in immunodeficiencies. He has published extensively on topics like viral transcriptional responses, gut microbiota interactions, and inflammatory biomarkers in CVID patients.

His articles highlight interdisciplinary approaches, integrating clinical data with molecular and epidemiological analyses. Notable studies address SARS-CoV-2 variants (Omicron vs Delta) and their impact on viral load and immune reactivation. He collaborates widely, with contributions to understanding cardiac sarcoidosis and diagnostic challenges in interstitial lung disease.

Fevang’s work emphasizes translational applications, such as optimizing therapies for inflammatory complications in CVID and elucidating long-term immune consequences of viral infections like Epstein-Barr. His research bridges basic immunology, clinical medicine, and public health, addressing both fundamental mechanisms and clinical management strategies.